Resistance to fluoroquinolone among Klebsiella spp strains producing extended-spectrum betalactamases isolated from urines;La résistance aux fluoroquinolones chez des souches de Klebsiella spp productrices de bêtalactamase à spectre étendu isolées dans les urines

Annales de Biologie Clinique

Volumn 67, Issue 5, 2009, Pages 553-556

  Tlamcani Z ^a   Ellaia, K ^b   Benomar, A ^b   Kabbaj, H ^b   Alaoui, A E ^b   Seffar, M ^b  

^a Laboratoire de Microbiologie   (France)

^b IBN SINA HOSPITAL   (Morocco)

Author keywords

Extended spectrum betalactamase; Klebsiella spp; Quinolone

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA; MICROBIOLOGY; RETROSPECTIVE STUDY; URINARY TRACT INFECTION; URINE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; KLEBSIELLA; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS; URINE;

KLEBSIELLA; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE;

EID: 73949146957     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2009.0363     Document Type: Article

References (14)

1. Nordmann P, Mammeri H. Résistance plasmidique aux quinolones. Antibiotiques 2007; 9: 246-53.
2. Skurnik D, Andremont A. Antibiothérapie sélectionnante: de la théorie à la pratique. Reanim 2006; 15: 198-204.
3. Legras JF. Ecologie bactérienne des infections dans un hôpital de gériatrie. J Pharm Clin 1998; 17: 232-40.
4. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-9.
5. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid encoded quinolone resistance protein QnrA with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 2005; 49: 118-25.
6. Robicsek A, Strahilevitz J, Jacoby GA. Fluoroquinolone modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12: 83-8.
7. Zogheib E, Dupont H. Entérobactéries multiré sistantes. Conférences d'actualisation de la SFAR 2005: 153-5.
8. Colodner R. Extended-spectrum beta-lactamases: a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005; 33: 104-7.
9. Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmidmediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989; 33: 1451-6.
10. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extendedspectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
11. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
12. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32: S94-103.
13. Lavilla S, González-López JJ, Sabaté M, García-Fernández A, Larrosa MN, Bartolomé RM. Prevalence of qnr genes among extendedspectrumß- lactamase-producing enterobacterial isolatesin Barcelona. Spain J Antimicrob Chimother 2008; 61: 291-5.
14. e réunion interdisciplinaire de chimiothérapie anti-infectieuse. Bordeaux, France: Communication, 2007.